

Ruben Niesvizky

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11766889/ruben-niesvizky-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

196
papers

7,721
citations

37
h-index

86
g-index

197
ext. papers

8,612
ext. citations

5.3
avg, IF

5.05
L-index

#	Paper	IF	Citations
196	Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. <i>New England Journal of Medicine</i> , 2007 , 357, 2133-42	59.2	1057
195	Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. <i>New England Journal of Medicine</i> , 2015 , 372, 142-52	59.2	928
194	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. <i>Leukemia</i> , 2012 , 26, 149-57	10.7	580
193	Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4976-84	2.2	290
192	Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. <i>Haematologica</i> , 2013 , 98, 1753-61	6.6	267
191	International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. <i>Journal of Clinical Oncology</i> , 2014 , 32, 587-600	2.2	255
190	Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2017 , 18, 1327-1337	21.7	248
189	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , 2011 , 117, 6063-73	2.2	234
188	Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. <i>Lancet Oncology</i> , 2014 , 15, 1503-1512	21.7	207
187	Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. <i>Clinical Cancer Research</i> , 2009 , 15, 5250-7	12.9	202
186	A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. <i>Cancer Research</i> , 2006 , 66, 7661-7	10.1	190
185	Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. <i>Blood</i> , 2009 , 114, 1729-35	2.2	170
184	Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. <i>Blood</i> , 2014 , 124, 1047-55	2.2	169
183	BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. <i>Blood</i> , 2008 , 111, 1101-9	2.2	158
182	IMWG consensus on maintenance therapy in multiple myeloma. <i>Blood</i> , 2012 , 119, 3003-15	2.2	150
181	A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. <i>Blood</i> , 2012 , 119, 2764-7	2.2	119
180	Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. <i>Blood</i> , 2013 , 122, 3122-8	2.2	119

179	Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3921-9	2.2	109
178	Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. <i>Cancer</i> , 2011 , 117, 336-42	6.4	102
177	Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. <i>European Journal of Haematology</i> , 2009 , 82, 426-32	3.8	98
176	Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. <i>Cancer Research</i> , 2005 , 65, 11345-53	10.1	95
175	The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2008 , 143, 46-53	4.5	91
174	Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 795-8	4.7	90
173	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. <i>Blood</i> , 2016 , 128, 1174-80	2.2	86
172	Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , 2013 , 163, 478-86	4.5	74
171	Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. <i>British Journal of Haematology</i> , 2007 , 138, 640-3	4.5	74
170	Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. <i>Clinical Cancer Research</i> , 2013 , 19, 2248-56 ^{12.9}	12.9	73
169	Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , 2009 , 146, 164-70	4.5	71
168	Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. <i>Blood</i> , 2012 , 120, 1095-106	2.2	70
167	Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2019 , 133, 1953-1963	2.2	63
166	Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3921-3930	2.2	58
165	Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. <i>Leukemia and Lymphoma</i> , 2009 , 50, 559-65	1.9	56
164	Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. <i>Leukemia and Lymphoma</i> , 2007 , 48, 2330-7	1.9	56
163	Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 3320-8	1.9	53
162	Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. <i>British Journal of Haematology</i> , 2017 , 177, 404-413	4.5	50

161	Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. <i>Journal of Clinical Oncology</i> , 2010 , 28, 132-5	2.2	49
160	Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. <i>American Journal of Hematology</i> , 2010 , 85, 664-9	7.1	46
159	Germline Lysine-Specific Demethylase 1 (LSD1) Mutations Confer Susceptibility to Multiple Myeloma. <i>Cancer Research</i> , 2018 , 78, 2747-2759	10.1	32
158	Gallium nitrate in multiple myeloma: prolonged survival in a cohort of patients with advanced-stage disease. <i>Seminars in Oncology</i> , 2003 , 30, 20-4	5.5	32
157	BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. <i>Blood</i> , 2013 , 121, 1982-5	2.2	31
156	CDK2 phosphorylation of Smad2 disrupts TGF-beta transcriptional regulation in resistant primary bone marrow myeloma cells. <i>Journal of Immunology</i> , 2009 , 182, 1810-7	5.3	30
155	Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. <i>Leukemia</i> , 2019 , 33, 1736-1746	10.7	29
154	Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 522-530.e1	2	28
153	Clinical characteristics of patients with relapsed multiple myeloma. <i>Cancer Treatment Reviews</i> , 2015 , 41, 827-35	14.4	26
152	Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. <i>Blood</i> , 2019 , 133, 147-155	2.2	24
151	IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , 2017 , 92, 746-751	7.1	21
150	How lenalidomide is changing the treatment of patients with multiple myeloma. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 88 Suppl 1, S23-35	7	20
149	Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay. <i>British Journal of Haematology</i> , 2016 , 173, 884-95	4.5	20
148	Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization. <i>Clinical Cancer Research</i> , 2013 , 19, 1534-48	12.9	19
147	IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease. <i>Modern Pathology</i> , 2014 , 27, 375-81	9.8	17
146	Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2588-2594	1.9	16
145	Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2019 , 134, 140-140	2.2	16
144	Dacetuzumab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma: Multiple Responses Observed in a Phase 1b Study.. <i>Blood</i> , 2009 , 114, 2870-2870	2.2	15

143	Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results. <i>Blood</i> , 2014 , 124, 82-82	2.2	15
142	ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD [®]) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study). <i>Blood</i> , 2015 , 126, 3040-3040 ^{2,2}		15
141	Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study). <i>Blood</i> , 2016 , 128, 3307-3307	2.2	15
140	Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 570-578.e1	2	14
139	Complications of multiple myeloma therapy, part 2: risk reduction and management of venous thromboembolism, osteonecrosis of the jaw, renal complications, and anemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010 , 8 Suppl 1, S13-20	7.3	14
138	Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients. <i>American Journal of Hematology</i> , 2019 , 94, 1132-1140	7.1	13
137	Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment. <i>Cancer Treatment Reviews</i> , 2012 , 38, 1012-9	14.4	13
136	Hematology and oncology clinical care during the coronavirus disease 2019 pandemic. <i>Ca-A Cancer Journal for Clinicians</i> , 2020 , 70, 349-354	220.7	13
135	Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma. <i>Leukemia Research</i> , 2014 , 38, 517-24	2.7	12
134	Oprozomib, Pomalidomide, and Dexamethasone (OPomd) in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1b Study (NCT01999335). <i>Blood</i> , 2015 , 126, 378-378	2.2	12
133	A phase 1b study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/ refractory multiple myeloma (RRMM): Preliminary results.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8539-8539	2.2	12
132	ClAPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2012 , 120, 77-77	2.2	11
131	Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis. <i>Blood Cancer Journal</i> , 2020 , 10, 35	7	10
130	Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis. <i>Blood</i> , 2011 , 118, 1876-1876	2.2	10
129	Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. <i>Blood Advances</i> , 2020 , 4, 5449-5459	7.8	10
128	Characteristics and outcomes of patients with multiple myeloma aged 21-40 [□] years versus 41-60 [□] years: a multi-institutional case-control study. <i>British Journal of Haematology</i> , 2016 , 175, 884-891	4.5	10
127	Results of a Phase I Trial of SGN-40 (Anti-huCD40 mAb) in Patients with Relapsed Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 3576-3576	2.2	9
126	A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma. <i>Blood</i> , 2012 , 120, 4029-4029	2.2	9

125	A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 930-937	4.7	8
124	High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019 , 54, 2027-2038	4.4	8
123	Best practices in the management of newly diagnosed multiple myeloma patients who will not undergo transplant. <i>Oncology</i> , 2010 , 24, 14-21	1.8	8
122	Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 663-677	2.9	7
121	Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 288-293	4.7	7
120	Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM).. <i>Blood</i> , 2005 , 106, 2574-2574	2.2	7
119	Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.. <i>Blood</i> , 2006 , 108, 3554-3554	2.2	7
118	Phase I Study of Lorvotuzumab Mertansine (IMGN901) In Combination with Lenalidomide and Dexamethasone In Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma - A Preliminary Safety and Efficacy Analysis of the Combination. <i>Blood</i> , 2010 , 116, 1934-1934	2.2	7
117	Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866). <i>Blood</i> , 2015 , 126, 30-30	2.2	7
116	Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391). <i>Blood</i> , 2015 , 126, 731-731	2.2	7
115	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. <i>American Journal of Hematology</i> , 2020 , 95, 503-509	7.1	6
114	Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. <i>Hematological Oncology</i> , 2020 , 38, 353-362	1.3	6
113	Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1364-1374	1.9	6
112	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.. <i>Lancet Haematology</i> , 2022 , 9, e143-e161	14.6	6
111	Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies. <i>Blood</i> , 2019 , 134, 5329-5329	2.3	6
110	A Phase I Humanized Anti-CD40 Monoclonal Antibody (SGN-40) in Patients with Multiple Myeloma.. <i>Blood</i> , 2005 , 106, 2572-2572	2.2	6
109	Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM).. <i>Blood</i> , 2009 , 114, 304-304	2.2	6
108	Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (MM). <i>Blood</i> , 2010 , 116, 1954-1954	2.2	6

107	Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study. <i>Blood</i> , 2011 , 118, 478-478	2.2	6
106	Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy In Relapsed Or Refractory Multiple Myeloma. <i>Blood</i> , 2013 , 122, 1955-1955	2.2	6
105	Molecular Predictors of Outcome and Drug Response in Multiple Myeloma: An Interim Analysis of the Mmrf CoMMpass Study. <i>Blood</i> , 2016 , 128, 194-194	2.2	6
104	Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma. <i>Blood Advances</i> , 2019 , 3, 603-611	7.8	6
103	Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 825-833	2.2	5
102	Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies. <i>Journal of Clinical Investigation</i> , 2017 , 127, 2066-2080	15.9	5
101	Randomized Multicenter Phase 3 Trial of High-Dose Dexamethasone (dex) with or without Oblimersen Sodium (G3139; Bcl-2 antisense; Genasense) for Patients with Advanced Multiple Myeloma (MM).. <i>Blood</i> , 2004 , 104, 1477-1477	2.2	5
100	Patient-Reported Quality of Life (QoL) in Elderly, Newly Diagnosed Multiple Myeloma (MM) Patients Receiving Bortezomib-Based Combinations: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study. <i>Blood</i> , 2011 , 118, 1864-1864	2.2	5
99	Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study. <i>Blood</i> , 2015 , 126, 377-377	2.2	5
98	High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma. <i>Blood</i> , 2015 , 126, 4258-4258	2.2	5
97	Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM). <i>Blood</i> , 2016 , 128, 4518-4518	2.2	5
96	Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma. <i>Blood Advances</i> , 2021 , 5, 367-376	7.8	5
95	Novel agents in myeloma: an exciting saga. <i>Cancer</i> , 2009 , 115, 236-42	6.4	4
94	Extended survival in advanced-stage multiple myeloma patients treated with gallium nitrate. <i>Leukemia and Lymphoma</i> , 2002 , 43, 603-5	1.9	4
93	Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial. <i>Blood</i> , 2019 , 134, 694-694	2.2	4
92	ClaPD (Clarithromycin/[Biaxin [®]], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2011 , 118, 635-635	2.2	4
91	Cardiac and Pulmonary Safety Profile of Single-Agent Carfilzomib From Four Phase 2 Studies in Patients with Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2012 , 120, 4037-4037	2.2	4
90	Effect of Renal and Hepatic Function on Pomalidomide Dose in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2014 , 124, 4754-4754	2.2	4

89	Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup. <i>Blood</i> , 2015 , 126, 1844-1844	2.2	4
88	Clarithromycin, pomalidomide, and dexamethasone (ClapD) in relapsed or refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8036-8036	2.2	4
87	Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2019 , 94, 539-545	7.1	3
86	Immunomodulatory agents changing the landscape of multiple myeloma treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 88 Suppl 1, S1-4	7	3
85	Daratumumab in Patients with Multiple Myeloma and Renal Impairment - Real-World Data from a Single-Center Institution. <i>Blood</i> , 2019 , 134, 5563-5563	2.2	3
84	BiRD (Biaxin [®] /Revlimid [®] /Dexamethasone) Combination Therapy (Rx) Results in High Complete Remissions (CR) and Overall Responses in Myeloma (MM) with Poor Prognostic Features.. <i>Blood</i> , 2005 , 106, 642-642	2.2	3
83	Relationship between Quality of Response to Bortezomib (btz) and Clinical Benefit in Multiple Myeloma (MM) in the APEX and SUMMIT Studies.. <i>Blood</i> , 2006 , 108, 3529-3529	2.2	3
82	A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.. <i>Blood</i> , 2009 , 114, 1877-1877	2.2	3
81	CHOP-R + Bortezomib as Initial Therapy for Mantle Cell Lymphoma (MCL).. <i>Blood</i> , 2009 , 114, 2682-2682	2.2	3
80	Phase I Study of Carfilzomib in Patients (Pts) with Relapsed and Refractory Multiple Myeloma (MM) and Varying Degrees of Renal Insufficiency.. <i>Blood</i> , 2009 , 114, 3877-3877	2.2	3
79	A Phase I Study of PD 0332991: Complete CDK4/6 Inhibition and Tumor Response In Sequential Combination with Bortezomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2010 , 116, 860-860	2.2	3
78	Car-Bird [Carfilzomib, Clarithromycin(Biaxin(R)), Lenalidomide/(Revlimid(R)), Dexamethasone) For Newly-Diagnosed Multiple Myeloma. <i>Blood</i> , 2013 , 122, 3216-3216	2.2	3
77	Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib. <i>Blood</i> , 2015 , 126, 4232-4232	2.2	3
76	Caspase-8 Inhibition Prevents the Cleavage and Degradation of E3 Ligase Substrate Receptor Cereblon and Potentiates Its Biological Function. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 605989	5.7	3
75	Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. <i>Blood Cancer Journal</i> , 2021 , 11, 101	7	3
74	Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2959-61 ⁹		2
73	Sustained disease control in transplant-ineligible patients: the role of continuous therapy. <i>Leukemia Research</i> , 2012 , 36 Suppl 1, S19-26	2.7	2
72	Conflicts of interest, authorship, and disclosures in industry-related scientific publications. <i>Mayo Clinic Proceedings</i> , 2010 , 85, 197-9; author reply 201-4	6.4	2

71	Impact of early response to sequential high-dose chemotherapy on outcome of patients with advanced myeloma and poor prognostic features. <i>Leukemia and Lymphoma</i> , 2002 , 43, 607-12	1.9	2
70	Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Efficacy and Safety Analyzed By Age Group. <i>Blood</i> , 2018 , 132, 3277-3277 ^{2,2}		2
69	Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma Receiving Daratumumab and Pomalidomide. <i>Blood</i> , 2019 , 134, 4876-4876	2.2	2
68	First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma. <i>Blood</i> , 2008 , 112, 3697-3697	2.2	2
67	Phase 3b UPFRONT Study: Interim Results From a Community Practice-Based Prospective Randomized Trial Evaluating Three Bortezomib-Based Regimens in Elderly, Newly Diagnosed Multiple Myeloma Patients.. <i>Blood</i> , 2009 , 114, 129-129	2.2	2
66	Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM). <i>Blood</i> , 2010 , 116, 1953-1953	2.2	2
65	Phase 1/2 Study of Oral MLN9708, A Novel, Investigational Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM). <i>Blood</i> , 2011 , 118, 479-479	2.2	2
64	Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma: Results From a Phase 1 Dose-Escalation Study. <i>Blood</i> , 2011 , 118, 816-816	2.2	2
63	Sequence Impact Of Pomalidomide and Carfilzomib On Treatment Response In Relapsed Multiple Myeloma. <i>Blood</i> , 2013 , 122, 1954-1954	2.2	2
62	Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 Endeavor Study (NCT01568866). <i>Blood</i> , 2015 , 126, 729-729	2.2	2
61	Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8525-8525	2.2	2
60	A phase 1b study of durvalumab (MEDI4736) alone or in combination with pomalidomide (POM) with or without low dose-dexamethasone (LoDEX) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS8072-TPS8072	2.2	2
59	Carfilzomib (K) in relapsed and refractory multiple myeloma (RRMM): Frailty subgroup analysis from phase III ASPIRE and ENDEAVOR.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8028-8028	2.2	2
58	Prospective study to measure the impact of MMprofiler on treatment intention in newly diagnosed multiple myeloma patients (PROMMIS).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8030-8030	2.2	2
57	Induction of sequential G1 arrest and synchronous S phase entry by reversible CDK4/CDK6 inhibition sensitizes myeloma cells for cytotoxic killing through loss of IRF-4.. <i>Blood</i> , 2009 , 114, 299-299	2.2	2
56	Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial. <i>EJHaem</i> , 2021 , 2, 375-384	0.9	2
55	Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2085-2087	1.9	2
54	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1885-1893	1.9	2

53	A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2021 , 96, 226-233	7.1	2
52	Caspase-8 Regulates the Antimyeloma Activity of Bortezomib and Lenalidomide. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021 , 379, 303-309	4.7	2
51	Lenalidomide in renal insufficiency [balancing the risks and benefits: response to Borrello. <i>British Journal of Haematology</i> , 2009 , 144, 447-448	4.5	1
50	Host Immune Responses Against CT Antigens in Multiple Myeloma Patients.. <i>Blood</i> , 2006 , 108, 3492-3492	2.2	1
49	Updated Survival Analyses after Prolonged Follow-Up of the Phase 2, Multicenter CREST Study of Bortezomib in Relapsed or Refractory Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 2717-2717	2.2	1
48	Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 3024-3024	2.2	1
47	A Comparison of Chemotherapy + G-CSF Versus Plerixafor (Mozobil) + G-CSF for Stem Cell Mobilization In Patients with Multiple Myeloma Treated with Lenalidomide. <i>Blood</i> , 2010 , 116, 2258-2258	2.2	1
46	Induction of Metabolic Impairment In Prolonged Early G1 Arrest Induced by CDK4/CDK6 Inhibition Sensitizes Myeloma Cells for Proteasome Inhibitor Killing During Subsequent S Phase Synchronization. <i>Blood</i> , 2010 , 116, 2989-2989	2.2	1
45	Lenalidomide Targets Myeloma Cells Preferentially During Prolonged Early G1 Arrest but Not Synchronization Into S Phase by Selective and Reversible Inhibition of CDK4/CDK6 through Loss of IRF-4. <i>Blood</i> , 2010 , 116, 449-449	2.2	1
44	A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplant in Multiple Myeloma. <i>Blood</i> , 2011 , 118, 2042-2042	2.2	1
43	Sensitizing shRNA Screen for Molecular Targets in CDK4/CDK6-Based Combination Therapy in Multiple Myeloma. <i>Blood</i> , 2014 , 124, 3440-3440	2.2	1
42	Car-Bird [Carfilzomib, Clarithromycin(Biaxin), Lenalidomide/(Revlimid), Dexamethasone) for Newly-Diagnosed Multiple Myeloma. <i>Blood</i> , 2014 , 124, 4761-4761	2.2	1
41	Identification of Initiating Trunk Mutations and Distinct Molecular Subtypes: An Interim Analysis of the Mmrf Compass Study. <i>Blood</i> , 2015 , 126, 722-722	2.2	1
40	MyPRSR Molecular Subtypes of Multiple Myeloma Represent All High-Risk FISH Translocations Included in the mSMART 2.0 and R-ISS Guidelines. <i>Blood</i> , 2016 , 128, 3264-3264	2.2	1
39	Sequencing of Proteasome Inhibitors in Patients with Multiple Myeloma. <i>Blood</i> , 2016 , 128, 4522-4522	2.2	1
38	Summary of treatment-emergent renal events from patients treated with single-agent carfilzomib from four phase II studies in relapsed and/or refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e18569-e18569	2.2	1
37	SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001). <i>Blood</i> , 2021 , 138, 2740-2740	2.2	1
36	Targeting Cdk4/6 in Combination Therapy Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma through Synergistic Mitochondria Depolarization.. <i>Blood</i> , 2007 , 110, 667-667	2.2	1

35	Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation. <i>Blood</i> , 2015 , 126, 500-500	2.2	1
34	MAGE-A Inhibits Apoptosis In Proliferating Multiple Myeloma Cells. <i>Blood</i> , 2010 , 116, 785-785	2.2	1
33	Preliminary Results of a Phase 2 Study of PD 0332991 in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2011 , 118, 2940-2940 ²	2.2	1
32	A phase 1 open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS7586-TPS7586	2.2	0
31	Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma. <i>Blood</i> , 2015 , 126, 2991-2991	2.2	0
30	Plasma Cell Myeloma Presenting With Amyloid-Laden Crystal-Negative Histiocytosis. <i>American Journal of Clinical Pathology</i> , 2020 , 154, 767-775	1.9	0
29	Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2021 , 96, 1554-1562	7.1	0
28	Novel therapies in monoclonal gammopathies. <i>Hematology</i> , 2012 , 17 Suppl 1, S121-4	2.2	
27	532. COVID-19 Pneumonia in Patients with Hematologic Malignancies A Report from the US Epicenter. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S333-S333	1	
26	Depsipeptide in the Treatment of Relapsed and Refractory Multiple Myeloma (MM): A Prospective Evaluation of the Cell Cycle.. <i>Blood</i> , 2004 , 104, 1497-1497	2.2	
25	Atypical Serum Immunofixation Pattern (ASIP) Development during Induction Therapy with BiRD for Newly Diagnosed Multiple Myeloma Correlates with a High Rate of Complete Remission.. <i>Blood</i> , 2007 , 110, 2737-2737	2.2	
24	Hematogenous Extramedullary Relapse in Multiple Myeloma - A Multicenter Retrospective Study in 127 Patients. <i>Blood</i> , 2018 , 132, 2004-2004	2.2	
23	Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution. <i>Blood</i> , 2019 , 134, 5644-5644	2.2	
22	Autologous Stem Cell Transplantation Outcomes in Patients with Myeloma and Renal Dysfunction. <i>Blood</i> , 2019 , 134, 5573-5573	2.2	
21	Harnessing the Epichaperome As a Therapeutic Approach in Multiple Myeloma. <i>Blood</i> , 2019 , 134, 4399-4399		
20	The Ki67/CD138 Ratio Independently Predicts Overall Survival in the Upfront Treatment of Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2014 , 124, 2016-2016	2.2	
19	A Comparison of Outcomes in the First-Line Treatment of Multiple Myeloma Presenting with Single Versus Multiple Monoclonal Paraproteins. <i>Blood</i> , 2014 , 124, 2038-2038	2.2	
18	Proteasome Inhibitor Treatment in Multiple Myeloma Can Mobilize Hematopoietic Stem Cells in the Absence of G-CSF. <i>Blood</i> , 2014 , 124, 2452-2452	2.2	

17	Effect of Autologous Transplantation on PFS2 in Myeloma Patients Receiving Front-Line Bird (clarithromycin, lenalidomide, dexamethasone). <i>Blood</i> , 2014 , 124, 5778-5778	2.2
16	The Clinical Utility of Bone Resorption and Bone Formation Markers in Multiple Myeloma. <i>Blood</i> , 2015 , 126, 5373-5373	2.2
15	Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8045-8045	2.2
14	Plasma cell proliferation by SynKii multiplex immunohistochemistry (mIHC) for clinical use in multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8056-8056	2.2
13	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. <i>Blood</i> , 2016 , 128, 3276-3276	2.2
12	Cooperative Suppression of MEIS2 Mediates Dexamethasone Enhancement of Lenalidomide Killing in Myeloma Cells. <i>Blood</i> , 2016 , 128, 3292-3292	2.2
11	MAGE-A3 Inhibits p53 and Promotes Proliferation and Survival in Multiple Myeloma.. <i>Blood</i> , 2009 , 114, 1795-1795	2.2
10	Selective inhibition of CDK4/CDK6 sensitizes bone marrow myeloma cells for killing by proteasome inhibitors carfilzomib and PR-047 through cell cycle-dependent expression of pro-apoptotic Noxa and Bim.. <i>Blood</i> , 2009 , 114, 2854-2854	2.2
9	The Effect of Bortezomib, Cyclophosphamide, and Filgrastim On Complete Remission Rates and CD34+ Stem Cell Collections in Multiple Myeloma.. <i>Blood</i> , 2009 , 114, 4349-4349	2.2
8	Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) Breaks Plateau Responses Following Initial Induction Therapy in Multiple Myeloma: Results of a Phase II Pilot Study.. <i>Blood</i> , 2009 , 114, 2311-2311	2.2
7	Updated Report of T-Bird (thalidomide, clarithromycin/[Biaxin [®]], lenalidomide/[Revlimid [®]], Dexamethasone) Therapy for Upfront Use In Symptomatic Multiple Myeloma. <i>Blood</i> , 2010 , 116, 3050-3050 ²	2.2
6	T-Bird (thalidomide, clarithromycin/[Biaxin [®]], lenalidomide/[Revlimid [®]], Dexamethasone) Therapy in Newly Diagnosed Symptomatic Multiple Myeloma. <i>Blood</i> , 2011 , 118, 2937-2937	2.2
5	Synergistic Loss of IRF4 and Induction of IRF7 Sensitizes Primary Myeloma Cells to IMiD Killing by IFN γ in Prolonged Early G1 Arrest Induced by CDK4/CDK6 Inhibition. <i>Blood</i> , 2012 , 120, 572-572	2.2
4	PET/CT Evaluation As a Prognostic Indicator In Relapsed Or Refractory Multiple Myeloma. <i>Blood</i> , 2013 , 122, 1878-1878	2.2
3	Relationship Of Serum Free Light Chain Reduction To Best Overall Response In Phase 2 Single-Agent and Combination Studies Of Carfilzomib In Patients With Relapsed Or Relapsed and/Or Refractory Multiple Myeloma. <i>Blood</i> , 2013 , 122, 1965-1965	2.2
2	High-dose lenalidomide and melphalan as conditioning for autologous stem cell transplantation in relapsed or refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 8021-8021	2.2
1	Treatment of multiple myeloma with carfilzomib in patients with renal injury. <i>Clinical Advances in Hematology and Oncology</i> , 2013 , 11, 605-6	0.6